Glucagon-like PEPTIDE-1

3 papers4 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

1 lab in 1 country
0 on aging of 9 trials, 4 with no results posted

Funders: National Institute of Diabetes and Digestive and Kidney Diseases and 6 more

Humans1

Outcomes

Cellular senescence

downin reviews1

1 study

Glucagon-like PEPTIDE-1 decreases cellular senescence.
“GLP-1 also influences immune cell function and alleviates hallmarks of senescence, thereby offering therapeutic potential beyond diabetes.”
Review
The multifaceted role of GLP-1 in metabolic disorders, chronic inflammation, and aging: Mechanisms and therapeutic potential
Metabolism: clinical and experimental10 Feb 2026

Associations

Sarcopenia

upin humans1

1 study

Glucagon-like PEPTIDE-1 is associated with sarcopenia in humans.
“Patients with sarcopenia exhibit significantly elevated levels of GLP-1 and CCK.”
Humansclinical cohort
NOVEL SERUM BIOMARKERS FOR SARCOPENIA: INSIGHTS FROM CLINICAL DATA AND STUDIES USING C2C12 MYOBLASTS
GSA 2024 abstract31 Dec 2024

Trials

0 on aging of 9

In trials

Critical illness
Phase 2Terminated1 trial
Hypoglycemia
Phase 2Terminated1 trial
Insulin resistance
Phase 1/2Terminated1 trial
Type 2 diabetes
Phase 1/2Terminated1 trial
Gastrointestinal disease
Phase 1Completed1 trial
Heart failure
Phase 1Completed1 trial

All 8

Irritable bowel syndrome
Phase 1Completed1 trial
Pediatric obesity
Early phase 1Terminated1 trial

Stopped

NCT00798590TerminatedCritical illness
PI left JHU
NCT00609154TerminatedInsulin resistance
Per source documents the study was terminated well in advance of targeted enrollment. A method for the analysis of insulin and proinsulin samples was never fully developed and validated. Study terminated upon expiration of IRB approval
NCT03500484TerminatedPediatric obesity
The study was initially paused due to COVID restrictions and then when able to resume, there was no longer funding.
NCT00686972Terminated
PI left JHU

Trial sponsors

Johns Hopkins University
2 trialsPhase 270 people
Albert Einstein College of Medicine
1 trialPhase 1/220 people
Uppsala University
2 trialsPhase 127 people
Papworth Hospital NHS Foundation Trust
1 trialPhase 110 people
University of Chicago
1 trialPhase 110 people
Yale University
1 trialEarly phase 113 people

Funding

18 grants since 2022

National Institute of Diabetes and Digestive and Kidney DiseasesUS$7.9mNational Institute of Allergy and Infectious DiseasesUS$5.4mNational Heart, Lung, and Blood InstituteUS$4.5m